worldwide cpulse exposure after JACC article media blitz...

worldwide cpulse exposure after JACC article media blitz
enrollments picking up and double digits is viable this quarter
plenty of cash cash in the bank
plenty of finance options
top ceo and management
ms kim olesson
likely FDA interim analysis / cuts trial time in half
corporate investor likely to make a move in the next 18 months
fully implantable potential
angina markets
no competition

all this for $5 a share ? , $80m market cap ?
---------------------------------------------

if we report 10+ enrollments in the next few weeks , we will be on our way to higher levels as the reason we dropped from 10 to 4 is because of slow enrollments.

Could this be the last opportunity to get in at this low price ?

trading has been choppy and negative with minimal volume but trust me someone is buying. we could retrace some more we could go back to the mid-higher 5 level , but be sure if enrollments are spot on which hopefully they are ,
this will run run run and you will see one hell of a short squeeze.

to conclude . BUY . this could be the last opportunity.